Skip to content

TriangleGet started

← Full study record

NCT04162210 · OUTCOME

Change From Baseline (CFB) in EORTC IL52 Score

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · Source last updated 2026-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: LEAST_SQUARES_MEAN
Unit: Scores on Scale
Interval / dispersion: 95% Confidence Interval
Time frame: Baseline (Day 1), every three weeks(Q3W) starting from week 4 until week 238

What was measured

European Organization for Research and Treatment of Cancer Item Library 52 (EORTC-QLQ-IL52) is disease symptoms domain from EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module) (EORTC QLQ-MY20). Disease symptoms domain of IL52 contain 6 items covering following concepts: bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. IL52 items are scored on 1 to 4 Likert-type scale, where 1 = Not at all, 2 = A little, 3 = Quite a bit, and 4 = Very much. A raw score is then calculated as mean of completed item responses across 6 disease symptom items. For symptom scales, this raw score is linearly transformed to a 0 to 100 scale using the formula: \[(raw score - 1) / 3\] × 100. Under this approach, a score of 0 indicates no symptoms across items, while a score of 100 indicates the highest level of symptom burden. Accordingly, higher scores indicate greater symptom burden or worse disease symptoms

Analysis population: ITT Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points.

Groups in this outcome

Belantamab Mafodotin

Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle

Pomalidomide Plus Dexamethasone

Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	218
Pomalidomide Plus Dexamethasone	107

Reported measurements

Disease Symptoms, CFB to Week 4

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	173
Pomalidomide Plus Dexamethasone	80

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-1.6	Not reported	-3.9	0.7	Not reported
Pomalidomide Plus Dexamethasone	-2.8	Not reported	-6.2	0.6	Not reported

Disease Symptoms, CFB to Week 7

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	144
Pomalidomide Plus Dexamethasone	77

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-1.4	Not reported	-4.0	1.1	Not reported
Pomalidomide Plus Dexamethasone	-4.2	Not reported	-7.8	-0.6	Not reported

Disease Symptoms, CFB to Week 10

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	128
Pomalidomide Plus Dexamethasone	65

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-1.5	Not reported	-4.3	1.3	Not reported
Pomalidomide Plus Dexamethasone	-1.7	Not reported	-5.7	2.2	Not reported

Disease Symptoms, CFB to Week 13

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	110
Pomalidomide Plus Dexamethasone	58

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-2.1	Not reported	-4.9	0.7	Not reported
Pomalidomide Plus Dexamethasone	-4.1	Not reported	-8.0	-0.3	Not reported

Disease Symptoms, CFB to Week 16

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	104
Pomalidomide Plus Dexamethasone	53

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-4.0	Not reported	-7.0	-1.1	Not reported
Pomalidomide Plus Dexamethasone	-3.3	Not reported	-7.3	0.8	Not reported

Disease Symptoms, CFB to Week 19

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	96
Pomalidomide Plus Dexamethasone	50

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-2.9	Not reported	-6.3	0.5	Not reported
Pomalidomide Plus Dexamethasone	-3.7	Not reported	-8.5	1.0	Not reported

Disease Symptoms, CFB to Week 22

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	95
Pomalidomide Plus Dexamethasone	42

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-2.8	Not reported	-6.1	0.5	Not reported
Pomalidomide Plus Dexamethasone	-4.7	Not reported	-9.5	0.1	Not reported

Disease Symptoms, CFB to Week 25

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	88
Pomalidomide Plus Dexamethasone	34

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-4.0	Not reported	-7.0	-1.1	Not reported
Pomalidomide Plus Dexamethasone	-3.6	Not reported	-8.2	0.9	Not reported

Disease Symptoms, Week 28

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	82
Pomalidomide Plus Dexamethasone	34

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-2.3	Not reported	-5.6	0.9	Not reported
Pomalidomide Plus Dexamethasone	-6.4	Not reported	-11.3	-1.4	Not reported

Disease Symptoms, CFB to Week 31

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	74
Pomalidomide Plus Dexamethasone	33

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-2.7	Not reported	-5.9	0.6	Not reported
Pomalidomide Plus Dexamethasone	-7.2	Not reported	-12.1	-2.2	Not reported

Disease Symptoms, CFB to Week 34

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	70
Pomalidomide Plus Dexamethasone	24

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-2.8	Not reported	-5.7	0.2	Not reported
Pomalidomide Plus Dexamethasone	-8.1	Not reported	-12.9	-3.2	Not reported

Disease Symptoms, CFB to Week 37

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	66
Pomalidomide Plus Dexamethasone	24

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-6.2	Not reported	-9.6	-2.8	Not reported
Pomalidomide Plus Dexamethasone	-7.1	Not reported	-12.9	-1.4	Not reported

Disease Symptoms, CFB to Week 40

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	65
Pomalidomide Plus Dexamethasone	23

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-5.9	Not reported	-9.0	-2.7	Not reported
Pomalidomide Plus Dexamethasone	-6.8	Not reported	-12.3	-1.3	Not reported

Disease Symptoms, CFB to Week 43

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	67
Pomalidomide Plus Dexamethasone	18

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-4.9	Not reported	-8.6	-1.2	Not reported
Pomalidomide Plus Dexamethasone	-8.6	Not reported	-15.6	-1.6	Not reported

Disease Symptoms, CFB to Week 46

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	63
Pomalidomide Plus Dexamethasone	13

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-7.1	Not reported	-10.0	-4.1	Not reported
Pomalidomide Plus Dexamethasone	-8.4	Not reported	-14.4	-2.3	Not reported

Disease Symptoms, CFB to Week 49

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	62
Pomalidomide Plus Dexamethasone	16

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-5.4	Not reported	-8.9	-1.9	Not reported
Pomalidomide Plus Dexamethasone	-8.3	Not reported	-15.2	-1.3	Not reported

Disease Symptoms, CFB to Week 52

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	60
Pomalidomide Plus Dexamethasone	17

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-7.7	Not reported	-10.7	-4.7	Not reported
Pomalidomide Plus Dexamethasone	-10.0	Not reported	-15.8	-4.1	Not reported

Disease Symptoms, CFB to Week 55

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	59
Pomalidomide Plus Dexamethasone	16

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-7.6	Not reported	-11.2	-3.9	Not reported
Pomalidomide Plus Dexamethasone	-5.4	Not reported	-12.5	1.7	Not reported

Disease Symptoms, CFB to Week 58

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	56
Pomalidomide Plus Dexamethasone	15

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-6.5	Not reported	-10.7	-2.3	Not reported
Pomalidomide Plus Dexamethasone	-5.5	Not reported	-13.6	2.6	Not reported

Disease Symptoms, CFB to Week 61

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	51
Pomalidomide Plus Dexamethasone	16

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-6.5	Not reported	-10.6	-2.4	Not reported
Pomalidomide Plus Dexamethasone	-3.2	Not reported	-10.7	4.4	Not reported

Disease Symptoms, CFB to Week 64

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	49
Pomalidomide Plus Dexamethasone	14

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-6.7	Not reported	-10.7	-2.8	Not reported
Pomalidomide Plus Dexamethasone	-9.4	Not reported	-16.8	-2.0	Not reported

Disease Symptoms, CFB to Week 67

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	48
Pomalidomide Plus Dexamethasone	15

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-9.9	Not reported	-13.3	-6.5	Not reported
Pomalidomide Plus Dexamethasone	-7.9	Not reported	-14.1	-1.7	Not reported

Disease Symptoms, CFB to Week 70

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	48
Pomalidomide Plus Dexamethasone	13

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-10.7	Not reported	-13.8	-7.6	Not reported
Pomalidomide Plus Dexamethasone	-12.3	Not reported	-18.1	-6.5	Not reported

Disease Symptoms, CFB to Week 73

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	40
Pomalidomide Plus Dexamethasone	14

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-8.7	Not reported	-12.7	-4.8	Not reported
Pomalidomide Plus Dexamethasone	-6.4	Not reported	-13.4	0.6	Not reported

Disease Symptoms, CFB to Week 76

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	42
Pomalidomide Plus Dexamethasone	15

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-7.2	Not reported	-11.0	-3.5	Not reported
Pomalidomide Plus Dexamethasone	-7.0	Not reported	-13.6	-0.5	Not reported

Disease Symptoms, CFB to Week 79

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	42
Pomalidomide Plus Dexamethasone	15

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-8.8	Not reported	-12.6	-5.0	Not reported
Pomalidomide Plus Dexamethasone	-10.5	Not reported	-17.1	-3.8	Not reported

Disease Symptoms, CFB to Week 82

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	43
Pomalidomide Plus Dexamethasone	15

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-6.9	Not reported	-10.5	-3.2	Not reported
Pomalidomide Plus Dexamethasone	-11.9	Not reported	-18.3	-5.4	Not reported

Disease Symptoms, CFB to Week 85

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	36
Pomalidomide Plus Dexamethasone	12

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-7.1	Not reported	-10.7	-3.5	Not reported
Pomalidomide Plus Dexamethasone	-13.0	Not reported	-19.4	-6.7	Not reported

Disease Symptoms, CFB to Week 88

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	36
Pomalidomide Plus Dexamethasone	12

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-6.7	Not reported	-10.5	-2.9	Not reported
Pomalidomide Plus Dexamethasone	-11.4	Not reported	-18.0	-4.7	Not reported

Disease Symptoms, CFB to Week 91

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	37
Pomalidomide Plus Dexamethasone	12

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-7.0	Not reported	-11.7	-2.4	Not reported
Pomalidomide Plus Dexamethasone	-3.8	Not reported	-12.0	4.4	Not reported

Disease Symptoms, CFB to Week 94

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	36
Pomalidomide Plus Dexamethasone	11

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-8.9	Not reported	-12.8	-5.0	Not reported
Pomalidomide Plus Dexamethasone	-9.1	Not reported	-16.2	-2.0	Not reported

Disease Symptoms, CFB to Week 97

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	30
Pomalidomide Plus Dexamethasone	10

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-6.4	Not reported	-10.6	-2.1	Not reported
Pomalidomide Plus Dexamethasone	-7.6	Not reported	-15.2	0.0	Not reported

Disease Symptoms, CFB to Week 100

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	35
Pomalidomide Plus Dexamethasone	10

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-7.8	Not reported	-12.7	-3.0	Not reported
Pomalidomide Plus Dexamethasone	-7.5	Not reported	-16.7	1.6	Not reported

Disease Symptoms, CFB to Week 103

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	34
Pomalidomide Plus Dexamethasone	9

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-7.8	Not reported	-12.2	-3.3	Not reported
Pomalidomide Plus Dexamethasone	-4.7	Not reported	-13.3	4.0	Not reported

Disease Symptoms, CFB to Week 106

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	33
Pomalidomide Plus Dexamethasone	6

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-7.9	Not reported	-12.2	-3.6	Not reported
Pomalidomide Plus Dexamethasone	-7.2	Not reported	-16.4	2.0	Not reported

Disease Symptoms, CFB to Week 109

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	34
Pomalidomide Plus Dexamethasone	8

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-7.7	Not reported	-11.7	-3.6	Not reported
Pomalidomide Plus Dexamethasone	-6.1	Not reported	-14.4	2.2	Not reported

Disease Symptoms, CFB to Week 112

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	29
Pomalidomide Plus Dexamethasone	7

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-9.9	Not reported	-14.4	-5.3	Not reported
Pomalidomide Plus Dexamethasone	-1.4	Not reported	-10.7	7.9	Not reported

Disease Symptoms, CFB to Week 115

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	30
Pomalidomide Plus Dexamethasone	8

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-7.9	Not reported	-12.0	-3.7	Not reported
Pomalidomide Plus Dexamethasone	-5.0	Not reported	-13.4	3.3	Not reported

Disease Symptoms, CFB to Week 118

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	30
Pomalidomide Plus Dexamethasone	8

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-6.5	Not reported	-11.7	-1.3	Not reported
Pomalidomide Plus Dexamethasone	-3.1	Not reported	-13.4	7.3	Not reported

Disease Symptoms, CFB to Week 121

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	26
Pomalidomide Plus Dexamethasone	8

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-2.3	Not reported	-10.0	5.3	Not reported
Pomalidomide Plus Dexamethasone	-6.7	Not reported	-21.3	7.8	Not reported

Disease Symptoms, CFB to Week 124

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	25
Pomalidomide Plus Dexamethasone	6

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-11.3	Not reported	-16.1	-6.5	Not reported
Pomalidomide Plus Dexamethasone	-7.3	Not reported	-16.9	2.3	Not reported

Disease Symptoms, CFB to Week 127

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	26
Pomalidomide Plus Dexamethasone	6

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-7.5	Not reported	-13.2	-1.8	Not reported
Pomalidomide Plus Dexamethasone	-10.9	Not reported	-22.6	0.7	Not reported

Disease Symptoms, CFB to Week 130

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	25
Pomalidomide Plus Dexamethasone	5

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-11.5	Not reported	-16.0	-6.9	Not reported
Pomalidomide Plus Dexamethasone	-5.1	Not reported	-14.6	4.5	Not reported

Disease Symptoms, CFB to Week 133

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	24
Pomalidomide Plus Dexamethasone	6

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-10.2	Not reported	-16.0	-4.4	Not reported
Pomalidomide Plus Dexamethasone	-4.2	Not reported	-15.8	7.5	Not reported

Disease Symptoms, CFB to Week 136

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	21
Pomalidomide Plus Dexamethasone	5

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-8.9	Not reported	-14.8	-3.1	Not reported
Pomalidomide Plus Dexamethasone	-14.4	Not reported	-26.4	-2.4	Not reported

Disease Symptoms, CFB to Week 139

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	21
Pomalidomide Plus Dexamethasone	6

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-11.5	Not reported	-15.6	-7.3	Not reported
Pomalidomide Plus Dexamethasone	-14.0	Not reported	-22.2	-5.8	Not reported

Disease Symptoms, CFB to Week 142

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	22
Pomalidomide Plus Dexamethasone	4

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-11.9	Not reported	-17.0	-6.8	Not reported
Pomalidomide Plus Dexamethasone	-11.1	Not reported	-22.1	-0.1	Not reported

Disease Symptoms, CFB to Week 145

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	18
Pomalidomide Plus Dexamethasone	5

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-10.0	Not reported	-14.7	-5.2	Not reported
Pomalidomide Plus Dexamethasone	-9.6	Not reported	-19.3	0.1	Not reported

Disease Symptoms, CFB to Week 148

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	19
Pomalidomide Plus Dexamethasone	4

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-8.7	Not reported	-14.3	-3.0	Not reported
Pomalidomide Plus Dexamethasone	-10.1	Not reported	-22.5	2.3	Not reported

Disease Symptoms, CFB to Week 151

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	21
Pomalidomide Plus Dexamethasone	4

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-11.2	Not reported	-15.4	-7.0	Not reported
Pomalidomide Plus Dexamethasone	-13.0	Not reported	-22.6	-3.3	Not reported

Disease Symptoms, CFB to Week 154

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	18
Pomalidomide Plus Dexamethasone	4

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-8.8	Not reported	-14.9	-2.8	Not reported
Pomalidomide Plus Dexamethasone	-1.5	Not reported	-15.1	12.1	Not reported

Disease Symptoms, CFB to Week 157

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	17
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-11.8	Not reported	-16.5	-7.1	Not reported
Pomalidomide Plus Dexamethasone	-9.1	Not reported	-20.3	2.1	Not reported

Disease Symptoms, CFB to Week 160

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	18
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-8.0	Not reported	-15.2	-0.9	Not reported
Pomalidomide Plus Dexamethasone	1.8	Not reported	-15.6	19.2	Not reported

Disease Symptoms, CFB to Week 163

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	18
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-10.7	Not reported	-16.1	-5.3	Not reported
Pomalidomide Plus Dexamethasone	-4.6	Not reported	-17.9	8.6	Not reported

Disease Symptoms, CFB to Week 166

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	15
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-12.8	Not reported	-18.6	-7.0	Not reported
Pomalidomide Plus Dexamethasone	-6.0	Not reported	-19.8	7.8	Not reported

Disease Symptoms, CFB to Week 169

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	17
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-10.0	Not reported	-15.8	-4.1	Not reported
Pomalidomide Plus Dexamethasone	-9.4	Not reported	-23.3	4.5	Not reported

Disease Symptoms, CFB to Week 172

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	13
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-15.0	Not reported	-19.9	-10.0	Not reported
Pomalidomide Plus Dexamethasone	-11.1	Not reported	-22.1	0.0	Not reported

Disease Symptoms, CFB to Week 175

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	12
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-16.1	Not reported	-21.4	-10.8	Not reported
Pomalidomide Plus Dexamethasone	-9.4	Not reported	-20.6	1.9	Not reported

Disease Symptoms, CFB to Week 178

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	14
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-15.9	Not reported	-19.5	-12.4	Not reported
Pomalidomide Plus Dexamethasone	-18.8	Not reported	-26.2	-11.5	Not reported

Disease Symptoms, CFB to Week 181

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	14
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-14.5	Not reported	-20.6	-8.3	Not reported
Pomalidomide Plus Dexamethasone	-11.1	Not reported	-23.8	1.7	Not reported

Disease Symptoms, CFB to Week 184

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	11
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-12.4	Not reported	-22.2	-2.5	Not reported
Pomalidomide Plus Dexamethasone	-8.1	Not reported	-26.8	10.6	Not reported

Disease Symptoms, CFB to Week 187

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	9
Pomalidomide Plus Dexamethasone	2

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-7.8	Not reported	-20.2	4.6	Not reported
Pomalidomide Plus Dexamethasone	-8.3	Not reported	-33.4	16.8	Not reported

Disease Symptoms, CFB to Week 190

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	10
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-6.7	Not reported	-17.5	4.1	Not reported
Pomalidomide Plus Dexamethasone	-5.2	Not reported	-25.9	15.5	Not reported

Disease Symptoms, CFB to Week 193

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	7
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-14.0	Not reported	-22.7	-5.2	Not reported
Pomalidomide Plus Dexamethasone	-11.3	Not reported	-23.7	1.1	Not reported

Disease Symptoms, CFB to Week 196

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	9
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-19.8	Not reported	-24.0	-15.6	Not reported
Pomalidomide Plus Dexamethasone	-16.0	Not reported	-23.1	-8.9	Not reported

Disease Symptoms, CFB to Week 199

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	7
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-11.8	Not reported	-25.2	1.6	Not reported
Pomalidomide Plus Dexamethasone	-7.6	Not reported	-25.9	10.8	Not reported

Disease Symptoms, CFB to Week 202

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	9
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-17.9	Not reported	-26.3	-9.4	Not reported
Pomalidomide Plus Dexamethasone	-9.9	Not reported	-23.6	3.9	Not reported

Disease Symptoms, CFB to Week 205

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	7
Pomalidomide Plus Dexamethasone	2

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.
Pomalidomide Plus Dexamethasone	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.

Disease Symptoms, CFB to Week 208

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	7
Pomalidomide Plus Dexamethasone	2

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.
Pomalidomide Plus Dexamethasone	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.

Disease Symptoms, CFB to Week 211

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	5
Pomalidomide Plus Dexamethasone	2

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.
Pomalidomide Plus Dexamethasone	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.

Disease Symptoms, CFB to Week 214

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	3
Pomalidomide Plus Dexamethasone	2

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.
Pomalidomide Plus Dexamethasone	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.

Disease Symptoms, CFB to Week 217

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	2
Pomalidomide Plus Dexamethasone	2

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.
Pomalidomide Plus Dexamethasone	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.

Disease Symptoms, CFB to Week 220

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	2
Pomalidomide Plus Dexamethasone	2

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.
Pomalidomide Plus Dexamethasone	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.

Disease Symptoms, CFB to Week 223

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	4
Pomalidomide Plus Dexamethasone	2

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.
Pomalidomide Plus Dexamethasone	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.

Disease Symptoms, CFB to Week 226

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	3
Pomalidomide Plus Dexamethasone	1

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.
Pomalidomide Plus Dexamethasone	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.

Disease Symptoms, CFB to Week 229

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	2
Pomalidomide Plus Dexamethasone	1

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.
Pomalidomide Plus Dexamethasone	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.

Disease Symptoms, CFB to Week 232

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	3
Pomalidomide Plus Dexamethasone	1

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.
Pomalidomide Plus Dexamethasone	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.

Disease Symptoms, CFB to Week 235

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	2
Pomalidomide Plus Dexamethasone	1

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.
Pomalidomide Plus Dexamethasone	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments.

Disease Symptoms, CFB to Week 238

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	0
Pomalidomide Plus Dexamethasone	1

Values in Scores on Scale · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Pomalidomide Plus Dexamethasone	NA	Not reported	NA	NA	Analysis was performed only if the number of subjects with analysable data at the current time point is \>= 10 in total across both treatments

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
-3.9
upper Limit
0.7
value
-1.6
group Id
OG001
lower Limit
-6.2
upper Limit
0.6
value
-2.8
denoms
counts
group Id
OG000
value
173
group Id
OG001
value
80
units
Participants
title
Disease Symptoms, CFB to Week 4
categories
measurements
group Id
OG000
lower Limit
-4.0
upper Limit
1.1
value
-1.4
group Id
OG001
lower Limit
-7.8
upper Limit
-0.6
value
-4.2
denoms
counts
group Id
OG000
value
144
group Id
OG001
value
77
units
Participants
title
Disease Symptoms, CFB to Week 7
categories
measurements
group Id
OG000
lower Limit
-4.3
upper Limit
1.3
value
-1.5
group Id
OG001
lower Limit
-5.7
upper Limit
2.2
value
-1.7
denoms
counts
group Id
OG000
value
128
group Id
OG001
value
65
units
Participants
title
Disease Symptoms, CFB to Week 10
categories
measurements
group Id
OG000
lower Limit
-4.9
upper Limit
0.7
value
-2.1
group Id
OG001
lower Limit
-8.0
upper Limit
-0.3
value
-4.1
denoms
counts
group Id
OG000
value
110
group Id
OG001
value
58
units
Participants
title
Disease Symptoms, CFB to Week 13
categories
measurements
group Id
OG000
lower Limit
-7.0
upper Limit
-1.1
value
-4.0
group Id
OG001
lower Limit
-7.3
upper Limit
0.8
value
-3.3
denoms
counts
group Id
OG000
value
104
group Id
OG001
value
53
units
Participants
title
Disease Symptoms, CFB to Week 16
categories
measurements
group Id
OG000
lower Limit
-6.3
upper Limit
0.5
value
-2.9
group Id
OG001
lower Limit
-8.5
upper Limit
1.0
value
-3.7
denoms
counts
group Id
OG000
value
96
group Id
OG001
value
50
units
Participants
title
Disease Symptoms, CFB to Week 19
categories
measurements
group Id
OG000
lower Limit
-6.1
upper Limit
0.5
value
-2.8
group Id
OG001
lower Limit
-9.5
upper Limit
0.1
value
-4.7
denoms
counts
group Id
OG000
value
95
group Id
OG001
value
42
units
Participants
title
Disease Symptoms, CFB to Week 22
categories
measurements
group Id
OG000
lower Limit
-7.0
upper Limit
-1.1
value
-4.0
group Id
OG001
lower Limit
-8.2
upper Limit
0.9
value
-3.6
denoms
counts
group Id
OG000
value
88
group Id
OG001
value
34
units
Participants
title
Disease Symptoms, CFB to Week 25
categories
measurements
group Id
OG000
lower Limit
-5.6
upper Limit
0.9
value
-2.3
group Id
OG001
lower Limit
-11.3
upper Limit
-1.4
value
-6.4
denoms
counts
group Id
OG000
value
82
group Id
OG001
value
34
units
Participants
title
Disease Symptoms, Week 28
categories
measurements
group Id
OG000
lower Limit
-5.9
upper Limit
0.6
value
-2.7
group Id
OG001
lower Limit
-12.1
upper Limit
-2.2
value
-7.2
denoms
counts
group Id
OG000
value
74
group Id
OG001
value
33
units
Participants
title
Disease Symptoms, CFB to Week 31
categories
measurements
group Id
OG000
lower Limit
-5.7
upper Limit
0.2
value
-2.8
group Id
OG001
lower Limit
-12.9
upper Limit
-3.2
value
-8.1
denoms
counts
group Id
OG000
value
70
group Id
OG001
value
24
units
Participants
title
Disease Symptoms, CFB to Week 34
categories
measurements
group Id
OG000
lower Limit
-9.6
upper Limit
-2.8
value
-6.2
group Id
OG001
lower Limit
-12.9
upper Limit
-1.4
value
-7.1
denoms
counts
group Id
OG000
value
66
group Id
OG001
value
24
units
Participants
title
Disease Symptoms, CFB to Week 37

denoms

counts
group Id
OG000
value
218
group Id
OG001
value
107
units
Participants

description

European Organization for Research and Treatment of Cancer Item Library 52 (EORTC-QLQ-IL52) is disease symptoms domain from EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module) (EORTC QLQ-MY20). Disease symptoms domain of IL52 contain 6 items covering following concepts: bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. IL52 items are scored on 1 to 4 Likert-type scale, where 1 = Not at all, 2 = A little, 3 = Quite a bit, and 4 = Very much. A raw score is then calculated as mean of completed item responses across 6 disease symptom items. For symptom scales, this raw score is linearly transformed to a 0 to 100 scale using the formula: \[(raw score - 1) / 3\] × 100. Under this approach, a score of 0 indicates no symptoms across items, while a score of 100 indicates the highest level of symptom burden. Accordingly, higher scores indicate greater symptom burden or worse disease symptoms

dispersion Type

95% Confidence Interval

groups

description
Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle
id
OG000
title
Belantamab Mafodotin
description
Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)
id
OG001
title
Pomalidomide Plus Dexamethasone

param Type

LEAST_SQUARES_MEAN

population Description

ITT Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points.

reporting Status

POSTED

time Frame

Baseline (Day 1), every three weeks(Q3W) starting from week 4 until week 238

title

Change From Baseline (CFB) in EORTC IL52 Score

type

SECONDARY

unit Of Measure

Scores on Scale

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice